PMID- 30319405
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 9
DP  - 2018
TI  - Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis.
PG  - 1049
LID - 10.3389/fphar.2018.01049 [doi]
LID - 1049
AB  - Clozapine is an efficacious atypical antipsychotic for treatment-refractory 
      schizophrenia. Clinical response and appearance of adverse events vary among 
      individual patients receiving clozapine, with genetic and non-genetic factors 
      potentially contributing to individual variabilities. Pharmacogenetic studies 
      investigate associations between genetic variants and drug efficacy and toxicity. 
      To date, most pharmacogenetic studies of clozapine have been conducted through 
      candidate gene approaches. A recent advance in technology made it possible to 
      perform comprehensive genetic mapping underlying clinical phenotypes and 
      outcomes, which allow novel findings beyond biological hypotheses based on 
      current knowledge. In this paper, we will summarize the studies on clozapine 
      pharmacogenetics that have extensively examined clinical response and 
      agranulocytosis. While there is still limited evidence on clozapine efficacy, 
      recent genome-wide studies provide further evidence of the involvement of the 
      human leukocyte antigen (HLA) region in clozapine-induced agranulocytosis.
FAU - Numata, Shusuke
AU  - Numata S
AD  - Department of Psychiatry, Institute of Biomedical Science, Tokushima University 
      Graduate School, Tokushima, Japan.
FAU - Umehara, Hidehiro
AU  - Umehara H
AD  - Department of Psychiatry, Institute of Biomedical Science, Tokushima University 
      Graduate School, Tokushima, Japan.
FAU - Ohmori, Tetsuro
AU  - Ohmori T
AD  - Department of Psychiatry, Institute of Biomedical Science, Tokushima University 
      Graduate School, Tokushima, Japan.
FAU - Hashimoto, Ryota
AU  - Hashimoto R
AD  - Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, 
      Japan.
AD  - Molecular Research Center for Children's Mental Development, United Graduate 
      School of Child Development, Osaka University, Osaka, Japan.
AD  - Department of Pathology of Mental Diseases, National Institute of Mental Health, 
      National Center of Neurology and Psychiatry, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180926
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6169204
OTO - NOTNLM
OT  - GWAS
OT  - SNP
OT  - agranulocytosis
OT  - clinical response
OT  - clozapine
OT  - pharmacogenetics
OT  - review
OT  - schizophrenia
EDAT- 2018/10/16 06:00
MHDA- 2018/10/16 06:01
PMCR- 2018/09/26
CRDT- 2018/10/16 06:00
PHST- 2018/06/11 00:00 [received]
PHST- 2018/08/30 00:00 [accepted]
PHST- 2018/10/16 06:00 [entrez]
PHST- 2018/10/16 06:00 [pubmed]
PHST- 2018/10/16 06:01 [medline]
PHST- 2018/09/26 00:00 [pmc-release]
AID - 10.3389/fphar.2018.01049 [doi]
PST - epublish
SO  - Front Pharmacol. 2018 Sep 26;9:1049. doi: 10.3389/fphar.2018.01049. eCollection 
      2018.